Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

515 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function.
Devriese LA, Witteveen PE, Mergui-Roelvink M, Smith DA, Lewis LD, Mendelson DS, Bang YJ, Chung HC, Dar MM, Huitema AD, Beijnen JH, Voest EE, Schellens JH. Devriese LA, et al. Br J Clin Pharmacol. 2015 Aug;80(2):253-66. doi: 10.1111/bcp.12606. Epub 2015 May 20. Br J Clin Pharmacol. 2015. PMID: 25677219 Free PMC article. Clinical Trial.
Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment.
de Vries Schultink AH, Suleiman AA, Schellens JH, Beijnen JH, Huitema AD. de Vries Schultink AH, et al. Eur J Clin Pharmacol. 2016 Jun;72(6):645-53. doi: 10.1007/s00228-016-2030-4. Epub 2016 Feb 26. Eur J Clin Pharmacol. 2016. PMID: 26915815 Free PMC article. Review.
Predictive Value of Microdose Pharmacokinetics.
van Nuland M, Rosing H, Huitema ADR, Beijnen JH. van Nuland M, et al. Among authors: huitema adr. Clin Pharmacokinet. 2019 Oct;58(10):1221-1236. doi: 10.1007/s40262-019-00769-x. Clin Pharmacokinet. 2019. PMID: 31030372 Review.
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs.
van der Velden DL, Hoes LR, van der Wijngaart H, van Berge Henegouwen JM, van Werkhoven E, Roepman P, Schilsky RL, de Leng WWJ, Huitema ADR, Nuijen B, Nederlof PM, van Herpen CML, de Groot DJA, Devriese LA, Hoeben A, de Jonge MJA, Chalabi M, Smit EF, de Langen AJ, Mehra N, Labots M, Kapiteijn E, Sleijfer S, Cuppen E, Verheul HMW, Gelderblom H, Voest EE. van der Velden DL, et al. Among authors: huitema adr. Nature. 2019 Oct;574(7776):127-131. doi: 10.1038/s41586-019-1600-x. Epub 2019 Sep 30. Nature. 2019. PMID: 31570881 Clinical Trial.
Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.
van Geel RMJM, van Brummelen EMJ, Eskens FALM, Huijberts SCFA, de Vos FYFL, Lolkema MPJK, Devriese LA, Opdam FL, Marchetti S, Steeghs N, Monkhorst K, Thijssen B, Rosing H, Huitema ADR, Beijnen JH, Bernards R, Schellens JHM. van Geel RMJM, et al. Among authors: huitema adr. Br J Cancer. 2020 Apr;122(8):1166-1174. doi: 10.1038/s41416-020-0776-z. Epub 2020 Mar 9. Br J Cancer. 2020. PMID: 32147669 Free PMC article. Clinical Trial.
515 results